Ipca Laboratories Ltd. is a global, consumer-led pharmaceutical company committed to improving lives since 1949. For over 60 years, Ipca has been a trusted healthcare partner across more than 120 countries spanning six continents. We are a fully integrated pharmaceutical company with capabilities in the manufacture of over 350 formulations and 80 APIs across multiple therapeutic segments, supported by 35 manufacturing facilities and 8 R&D centers. Our state-of-the-art R&D center in Mumbai, along with our advanced manufacturing facility in Pithampur, Madhya Pradesh, specializes in the development and biomanufacturing of monoclonal antibody (mAb) biosimilars. The facility adheres to global GMP standards and produces high-potency biosimilars for both domestic and regulated international markets, including the USA and Europe. It is equipped with single-use Drug Substance (DS) and Drug Product (DP) systems, automated processes, a zero liquid discharge effluent treatment plant, and environmentally sustainable practices. Ipca is also among the fastest-growing companies within the top 20 pharmaceutical companies in India. We believe there is strong potential for collaboration between our organizations in the biosimilars space. Possible areas of partnership include: Drug Substance and Drug Product development and manufacturing In-licensing and out-licensing of monoclonal antibody (mAb) molecules Technology transfer and know-how sharing Peer-to-peer biosimilar business development across global markets We have developed a robust biosimilar pipeline (mAb and non-mAb) targeting key markets including the EU, UK, USA, Canada, Japan, India, and Rest of the World (ROW).
Iowa Economic Development Authority
The Iowa Economic Development Authority’s (IEDA) mission is to strengthen economic and community vitality by building partnerships and leveraging resources to make Iowa the choice for people and business. Through two main divisions – business development and community development – IEDA administers several state and federal programs to meet its goals of assisting individuals, communities and businesses. IEDA works to achieve its mission and goals to benefit Iowans while maintaining a high level of transparency. | Iowa’s bio-based economy encompasses development of industrial enzymes, livestock genetics, seed genetics, human gene research, nutraceuticals, pharmaceuticals, advanced bio-composites, biomass technologies and healthy foods/beverages. Iowa is home to global companies known for developing new plant hybrids for grains, leading genetics for beef and dairy production and many contributions to the rapid expansion of enzymes used for ethanol bioprocessing. Iowa is perfectly positioned with its central location and has a diversified and robust economy. Companies operating in Iowa benefit from a business-friendly state government, business-minded tax incentives and a skilled and productive workforce within a right-to-work state. The Iowa Economic Development Authority provides incentives, job training funding and confidential site selection services to businesses looking to locate or expand operations in the state of Iowa. For more information on Iowa’s business advantages, visit iowaeda.com. | Iowa is a top spot for insurance, ranking first in the U.S. in insurance industry output as a percent of GDP. Iowa’s leading position in the industry is seen through more than 7,400 finance and insurance companies that are housed in the state with a workforce of nearly 92,000 talented professionals. Companies in Iowa benefit from a pro-business environment with one of the lowest insurance premium tax rates in the nation, which is being lowered from 1% to 0.9%, that is complemented by a highly educated, stable talent pipeline and strategic central geographic location that conveniently serves clients on both coasts. The state’s extensive insurance leadership has established numerous advancements in insurtech that are revolutionizing the industry. Insurtech entrepreneurs find themselves with a truly unique ecosystem of support in Iowa and can easily access mentorship and guidance from global companies and accelerators, as well as educational institutions and responsive state agencies. The Iowa Economic Development Authority is committed to collaboration and innovation with resources and connections that can help your company start, grow and thrive. To learn more, visit iowaeda.com.
Industrial Technology Research Institute (ITRI)
ITRI is committed to driving the development of various industries with its outstanding technology and research abilities in hopes to create economic values and promote social well-being. In addition to playing a role of researcher and developer in the fields of medicine as well as medical devices, it has also established a complete structure of CRO (Contract Research Organizations) and CDMO (Contract Development & Manufacturing Organization) services. The one-stop biomedical services platform of ITRI provides assistance in a wide range of scopes, including research and development, model translation, GXP trial production, pre-clinical/clinical trial, post-marketing consultation, etc. This mechanism makes it possible for domestic manufacturers to lower their initial cost of investment, and accelerate their research and development. ◆ Regulation Consulting: FDA/TFDA/CE application, medical device verification/export, medical device/medicine registration, IRB document organization, clinical trial application, and more. ◆ Licencing: Bio-IT, diagnostics and precision medicine technology, regeneration medicine technology, natural medicine and healthcare technology, targeted drug and delivery technology. ◆ Prototyping: Domestic supply chain linkage, medical device design control, market analysis, strategy analysis of regulation in commercialization, and more. ◆ Preclinical/Clinical Trial: Functional safety assessments, clinical research organization linkage, clinical evaluation and analysis, clinical trial planning, clinical trial analysis and reports. ◆ Other Services: Quality system consulting, commercialization consulting, smart health solutions, software validation, medical device risk management, information security risk evaluation, technical documents preparation, business ecosystem linkage, and more.
Indiana Pavillion
The Indiana Pavilion is brought to you by BioCrosscrossroads. BioCrossroads is a catalyst for Indiana’s diverse and growing life sciences industry, supporting collaboration, expertise, and investments that fuel innovation and transform global health.
Indiana Biosciences Research Institute
The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life. By connecting early-stage biotech companies with cutting-edge life science discoveries—and backed by the mission and resources of industry leaders, investors, and philanthropic partners—IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures. To learn more, visit www.indianabiosciences.org.
Health Ever Bio-Tech Co., Ltd.
Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative botanical drugs backed with scientific and medical evidences for today’s great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of botanical new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide botanical new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots. | Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative new drugs backed with scientific and medical evidences for today’s great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of innovative new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide innovative new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots.
Genome Canada
Genome Canada is a national not-for-profit organization addressing Canada’s greatest challenges and opportunities through research and innovation in genomics and associated biosciences. With a 25-year track record of impact across sectors, a pan-Canadian network of six regional Genome Centres, and strong partnerships across the public, private, non-profit and academic sectors at home and internationally, we translate research into real-world impact in health, climate action and food security. Learn more at genomecanada.ca. Génome Canada est un organisme national sans but lucratif qui s’attaque aux plus grands défis et aux plus grandes possibilités du Canada par la recherche et l’innovation en génomique et dans les biosciences connexes. Forts d’un bilan de 25 ans d’influence sur les communautés, d’un réseau pancanadien de six centres de génomique régionaux et de solides partenariats dans les secteurs public, privé, sans but lucratif et universitaire au Canada et à l’étranger, nous nous efforçons de transformer la recherche en solutions concrètes dans les domaines de la santé, du climat et de la sécurité alimentaire. Pour en savoir plus, visitez genomecanada.ca. | Genome Canada is a national not-for-profit leading large-scale research missions that translate excellent science into economic, health and environmental solutions. We align Canada’s genomics ecosystem for impact. | Génome Canada est un organisme national sans but lucratif qui dirige des missions de recherche à grande échelle visant à traduire l’excellence de la science en solutions économiques, sanitaires et environnementales. Nous alignons l’écosystème génomique du Canada en vue d’un impact.
EMD Serono
EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.emdseronooncology.com | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress. | In Healthcare, we are at the forefront of developing pioneering therapies – boldly aiming to meaningfully change the lives of patients, their families, and their caregivers. We are unlocking leaps in highly specialized fields with significant unmet medical needs. We leverage internal discoveries and external partnerships to serve patients who need it most across all continents. As one company, science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are sparking discovery, elevating humanity. | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. EMD Serono Aspires to create, improve and prolong lives — As One for Patients. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress.
DXY Insight Database
DXY Insight Database is a leading global drug competitive intelligence platform with deep China insights, delivering multi-dimensional intelligence across the entire drug lifecycle — from preclinical research through post-market approval — and empowering enterprises to make more precise decisions and work more efficiently. Key highlights include: · 80,000+ drug pipelines (22,000+ originated by Chinese companies) · 25,000+ pharmaceutical companies (11,000+ based in China) · Tracking of 9,000+ targets and 14,000+ BD transactions
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.